경구 경점막 약물 시장 규모 조사 : 제품 유형별, 투여 경로별, 적응증별, 유통 채널별, 지역별 예측(2022-2032년)

Global Oral Transmucosal Drugs Market is valued at approximately USD 34.37 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.71% over the forecast period 2024-2032. Oral transmucosal drugs are a unique class of medications administered through the mucous membranes in the mouth, such as the buccal or sublingual areas. This method of drug delivery ensures that the medication is directly absorbed into the bloodstream, bypassing the gastrointestinal tract and liver, which enhances bioavailability and provides a faster onset of action. Such drugs are often employed in pain management, hormone replacement therapy, and conditions requiring rapid systemic effects. They present a non-invasive alternative to injections and traditional oral tablets.

The Global Oral Transmucosal Drugs Market growth is propelled by the rising demand for oral transmucosal drugs, driven by the increasing prevalence of chronic diseases. Innovations in drug delivery technologies further fuel market expansion, making these medications more effective and accessible. Moreover, rising investments in pharmaceutical R&D are anticipated to create lucrative opportunities for the market. However, the market faces challenges such as stringent regulatory requirements for drug approval and high costs associated with research and development activities.

The key regions considered for the Global Oral Transmucosal Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America dominated the oral transmucosal drugs market, holding the largest market share. This dominance is expected to continue throughout the forecast period, supported by a favorable regulatory environment that encourages pharmaceutical companies to invest in research and development of these medications, thereby fueling demand. Furthermore, the market in Asia Pacific is anticipated to develop at the fastest rate over the forecast period 2024-2032.

Major market players included in this report are:

• Aquestive Therapeutics, Inc
• Jazz Pharmaceuticals, plc.
• Pfizer Inc.
• C.L.Pharm Co., Ltd.
• Cure Pharmaceutical
• IntelGenx Technologies Corp
• NAL Pharma
• Novartis AG
• Teva Pharmaceutical Industries Limited
• ZIM Laboratories Limited

The detailed segments and sub-segment of the market are explained below:

By Product Type:

• Tablets
• Films
• Liquid & Spray
• Other Product Types

By Route of Administration:

• Sublingual Mucosa
• Buccal Mucosa
• Other Routes of Administration

By Indication:

• Opioid Dependence
• Nausea and Vomiting
• Erectile Dysfunction
• Neurological Disorders
• Other Indications

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

Table of Contents

Chapter 1. Global Oral Transmucosal Drugs Market Executive Summary

• 1.1. Global Oral Transmucosal Drugs Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Product Type
  • 1.3.2. By Route of Administration
  • 1.3.3. By Indication
  • 1.3.4. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Oral Transmucosal Drugs Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Oral Transmucosal Drugs Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Demand for Oral Transmucosal Drugs
  • 3.1.2. Advancements in Drug Delivery Technologies
  • 3.1.3. Increasing Prevalence of Chronic Diseases
• 3.2. Market Challenges
  • 3.2.1. Stringent Regulatory Requirements for Drug Approval and Commercialization
  • 3.2.2. High Cost Associated with Research and Development Activities
• 3.3. Market Opportunities
  • 3.3.1. Favorable Regulatory Environments
  • 3.3.2. Investments in Pharmaceutical R&D
  • 3.3.3. Emerging Markets in various economies

Chapter 4. Global Oral Transmucosal Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Oral Transmucosal Drugs Market Size & Forecasts by Product Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Oral Transmucosal Drugs Market: Product Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Tablets
  • 5.2.2. Films
  • 5.2.3. Liquid & Spray
  • 5.2.4. Other Product Types

Chapter 6. Global Oral Transmucosal Drugs Market Size & Forecasts by Route of Administration 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Oral Transmucosal Drugs Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Sublingual Mucosa
  • 6.2.2. Buccal Mucosa
  • 6.2.3. Other Routes of Administration

Chapter 7. Global Oral Transmucosal Drugs Market Size & Forecasts by Indication 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Oral Transmucosal Drugs Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Opioid Dependence
  • 7.2.2. Nausea and Vomiting
  • 7.2.3. Erectile Dysfunction
  • 7.2.4. Neurological Disorders
  • 7.2.5. Other Indications

Chapter 8. Global Oral Transmucosal Drugs Market Size & Forecasts by Distribution Channel 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Oral Transmucosal Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies
  • 8.2.3. Online Pharmacies

Chapter 9. Global Oral Transmucosal Drugs Market Size & Forecasts by Region 2022-2032

• 9.1. North America Oral Transmucosal Drugs Market
  • 9.1.1. U.S. Oral Transmucosal Drugs Market
    • 9.1.1.1. Product Type breakdown size & forecasts, 2022-2032
    • 9.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 9.1.1.3. Indication breakdown size & forecasts, 2022-2032
    • 9.1.1.4. Distribution Channel breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada Oral Transmucosal Drugs Market
• 9.2. Europe Oral Transmucosal Drugs Market
  • 9.2.1. U.K. Oral Transmucosal Drugs Market
  • 9.2.2. Germany Oral Transmucosal Drugs Market
  • 9.2.3. France Oral Transmucosal Drugs Market
  • 9.2.4. Spain Oral Transmucosal Drugs Market
  • 9.2.5. Italy Oral Transmucosal Drugs Market
  • 9.2.6. Rest of Europe Oral Transmucosal Drugs Market
• 9.3. Asia-Pacific Oral Transmucosal Drugs Market
  • 9.3.1. China Oral Transmucosal Drugs Market
  • 9.3.2. India Oral Transmucosal Drugs Market
  • 9.3.3. Japan Oral Transmucosal Drugs Market
  • 9.3.4. Australia Oral Transmucosal Drugs Market
  • 9.3.5. South Korea Oral Transmucosal Drugs Market
  • 9.3.6. Rest of Asia Pacific Oral Transmucosal Drugs Market
• 9.4. Latin America Oral Transmucosal Drugs Market
  • 9.4.1. Brazil Oral Transmucosal Drugs Market
  • 9.4.2. Mexico Oral Transmucosal Drugs Market
  • 9.4.3. Rest of Latin America Oral Transmucosal Drugs Market
• 9.5. Middle East & Africa Oral Transmucosal Drugs Market
  • 9.5.1. Saudi Arabia Oral Transmucosal Drugs Market
  • 9.5.2. South Africa Oral Transmucosal Drugs Market
  • 9.5.3. Rest of Middle East & Africa Oral Transmucosal Drugs Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Aquestive Therapeutics, Inc.
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Jazz Pharmaceuticals, plc.
  • 10.3.3. Pfizer Inc.
  • 10.3.4. C.L.Pharm Co., Ltd.
  • 10.3.5. Cure Pharmaceutical.
  • 10.3.6. IntelGenx Technologies Corp.
  • 10.3.7. NAL Pharma
  • 10.3.8. Novartis AG
  • 10.3.9. Teva Pharmaceutical Industries Limited.
  • 10.3.10. ZIM Laboratories Limited

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes